Vaporized mebufotenin leads to improvement in treatment‐resistant depression
The Brown University Psychopharmacology Update June 28, 2026 Peer reviewed DOI: 10.1002/pu.31471 via OpenAlex
Summary
An individualized one-day dosing regimen of vaporized mebufotenin (5-MeO-DMT) significantly improved depressive symptoms in adults with treatment-resistant depression compared to placebo. The study, a Phase 2b trial, reported no serious adverse events over the 7-day duration. These results were published online on March 2, 2026, in JAMA Psychiatry.
Study at a glance
| Design | Phase 2b trial |
|---|---|
| Population | adults with treatment-resistant depression |
| Key finding | Vaporized mebufotenin was more effective than placebo in improving depressive symptoms. |
Abstract
An individualized one‐day dosing regimen of a vaporized formulation of the psychedelic mebufotenin (5‐methoxy‐ N,N ‐dimethyltryptamine; 5‐MeO‐DMT) was more effective than placebo in improving depressive symptoms in adults with treatment‐resistant depression, a Phase 2b trial has found. No serious treatment‐emergent adverse events were reported during the 7‐day study. Results were published online March 2, 2026 in JAMA Psychiatry .